Canixin DHPPi/L

Страна: Велика Британія

мова: англійська

Джерело: VMD (Veterinary Medicines Directorate)

Активний інгредієнт:

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Доступна з:

Virbac

Код атс:

QI07AI02

ІПН (Міжнародна Ім'я):

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae

Фармацевтична форма:

Lyophilisate for suspension for injection

Тип рецепту:

POM-V - Prescription Only Medicine – Veterinarian

Терапевтична група:

Dogs

Терапевтична области:

Live Viral and Inactivated Bacterial Vaccine

Статус Авторизація:

Authorized

Дата Авторизація:

2012-05-14

Характеристики продукта

Revised: February 2021
AN: 01013/2020
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
CANIXIN DHPPi/L lyophilisate and suspension for suspension for
injection for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCES
Lyophilisate
Live attenuated canine distemper virus (CDV) - Lederle
strain
10
3.0 -
10
4.9
CCID
50
*
Live attenuated canine adenovirus type 2 (CAV-2) -
Manhattan strain
10
4.0
-
10
6.0
CCID
50
*
Live attenuated canine parvovirus (CPV) - CPV780916
strain
10
5.0
-
10
6.8
CCID
50
*
Live attenuated canine parainfluenza virus (CPIV) -
Manhattan strain
10
5. 0
-
10
6.9
CCID
50
*
*
Cell culture infectious dose 50%
Suspension
Inactivated _Leptospira interrogans_:
- serogroup Canicola serovar Canicola, strain 601903
4350 - 7330 U**
- serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain
601895
4250 - 6910 U**
** Antigenic mass ELISA units
EXCIPIENTS
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Lyophilisate and suspension for suspension for injection.
Lyophilisate: White lyophilisate
Suspension: Translucent liquid
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Revised: February 2021
AN: 01013/2020
Page 2 of 6
For active immunisation of dogs from 8 weeks of age to:
-
prevent mortality and clinical signs caused by canine distemper virus;
-
prevent mortality and clinical signs caused by canine adenovirus type
1;
-
prevent clinical signs and mortality and reduce excretion caused by
canine
parvovirus in challenge studies performed with a CPV-2b strain;
-
prevent clinical signs and reduce excretion caused by canine
parvovirus in a
challenge study performed with a CPV-2c strain;
-
reduce
respiratory
clinical
signs
and
viral
excretion
caused
by
canine
parainfluenza virus and canine adenovirus type 2;
-
prevent mortality and reduce infection, clinical signs, kidney
colonisation, renal
lesions and urine shedding of _L._Canicola;
-
reduce infect